Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Merger or Acquisition (October 2018)
5 slides from Mayne Pharma's merger presentation, Oct 26, 2018
Slide 1: Acquisition of FDA-approved halobetasol foam
For personal use only Acquisition of FDA-approved halobetasol foam Mayne Pharma Group Limited 26 October 2018 1
Slide 2: Transaction overview
Transaction overview For personal use only ● Mayne Pharma has acquired US and Australian rights to halobetasol foam and related assets for an investment of: - Up to US$32.0m comprising: • An upfront cash payment of US$10.0m; • US$5.0m at commercial launch expected in 1Q CY19; • Up to US$17.0m of con
Slide 3: Halobetasol foam acquisition overview
Halobetasol foam acquisition overview For personal use only Mayne Pharma has acquired US and Australian rights to halobetasol foam and related assets ● Halobetasol foam, 0.05% is a potent corticosteroid for the treatment of plaque psoriasis in patients aged 18+ years old ● Clinically differentiated
Slide 4: Psoriasis overview
Psoriasis overview For personal use only ● Psoriasis is a chronic, non-contagious, inflammatory Pharmaceutical psoriasis treatment skin condition that appears as red patches covered with silvery flakes often found on the elbows, scalp Psoriasis and knees but can also affect other parts of the body ●
Slide 5: US psoriasis market overview
US psoriasis market overview1 For personal use only Topical psoriasis market by value2 Market opportunity Mild – Moderate Moderate – Severe 13% Potent corticosteroid Psoriasis Psoriasis 0-10% of body affected >10% of body affected Combination 25% US$900m 5.6m people of which 1.9m people Vitamin D 62
Mayne Pharma Group — Merger or Acquisition (October 2018) on 6ix